Abyssinia Biologics
No bio yet
This person is not in any teams
This person is not in any offices
Abyssinia Biologics
Abyssinia is altering the world's understanding of Alzheimer's Disease from diagnostic assays with the potential for early diagnosis to treatment approaches addressing novel disease causes. Abyssinia's lead candidate ABY-71A1 is a IgG1 mAb with a high specificity for toxic soluble amyloid oligomers, which is backed up by ourcompanion diagnostic assay for soluble amyloid in plasma & CSF. Abyssinia was founded in 2017.